Regulatory Compliance Software help drug companies identify, monitor and manage drug risks effectively. A reliable pharmacovigilance system helps pharmaceutical companies work in tandem with drug regulatory authorities.
Archive for Pharmaceutical Companies
Mar
09
Analyzing Mesothelioma Clinical Trials
Posted by: | Comments
Analyzing Mesothelioma Clinical Trials
Who conducts mesothelioma clinical trials?
Mesothelioma trials are conducted to study and experiment on the effectiveness of the new drugs and treatments invented for mesothelioma.Visit here http://mesotheliomatreatment-option.blogspot.com
The cancer institutes, research centers and hospitals mostly conduct these trials. Doctors, private organizations and others fund them. Certain pharmaceutical companies and drug manufacturers also conduct and fund mesothelioma clinical trials. They do this because they want volunteers to test their new drugs.
How to find mesothelioma clinical trials?
The advertisement for clinical trials appears in cancer centers, newspapers and magazines. Many people enlist for the clinical trials out of their own will. They speak cancer research centers and doctors and express their wish to volunteer for clinical trial. These people do so because they want to help other cancer patients who suffer like them. However, apart from all this, the best place to check out about clinical trials is online. Lots of websites gives information about the trials taking place and how volunteers can participate in them.
What are the phases of mesothelioma clinical trials?
Mesothelioma clinical trials are normally done in three phases:
1) Phase I trial: This trial involves only very few people. It is used to test the effectiveness of the new drugs or new type of treatment.
2) Phase II trial: This trial involves a larger group of subjects. The drug’s side effects, safety, dosage and effectiveness are tested using this trial.
3) Phase III trial: This trial involves a huge amount of people from various cancer treatment Centers simultaneously. This is a comparative trial in which the new medicine or type of treatment is compared to the existing ones. The comparative risks, benefits and effectiveness are analyzed.
What are the benefits of mesothelioma clinical trials?
There are many benefits of taking part in a mesothelioma clinical trial. Some of these benefits are listed below:
1) The patients who participate in mesothelioma clinical trials have easy access to the latest drugs and treatments that have been invented. These are not available for the other non-participants.
2) Normally, the new drugs and treatments are invented after much research and experiments. So, they are more effective and work well than the current drugs and treatments. So, the volunteers would highly benefit from these new drugs and treatments.
3) The medical research personnel and doctors consider a participant in a mesothelioma clinical trial a very special person. So, the volunteer gets lots of special and close medical attention on all aspects of the treatment.
4) Every clinical trial helps medical science advance one more step. This will define the medicines and treatments of the future. The destiny of millions depends on these advancements.
5) The volunteers for mesothelioma clinical trials are contributing to a huge social cause. It is because of them that many find their life during the disease more comfortable.
The above are the various benefits for volunteers taking part in mesothelioma clinical trials.
What are the risks involved in participating in a mesothelioma clinical trial?
A mesothelioma clinical trial is only an experimental study of new drugs and new types of treatments. These may be advantageous or disadvantageous. The main risks associated with taking part in a mesothelioma clinical trial are as follows:
1) The new medicine or new method of treatment may not be better than the current one. Sometimes, it may even worsen the condition.
2) Mostly, medical researchers and doctors are not aware of the exact side effects and consequences of the new medicines or types of treatment invented by them. So, there may also arise to be risky side effects because of the clinical trial.
3) The clinical trial treatments may not be covered by health insurance. So,
It is always better to find out about this before going in for the mesothelioma clinical trial.
4) A clinical trial involves much more interaction between the doctor and the patient. So, the patient will have to go to the hospital more often. These frequent visits may be tiresome and irritating during an uncomfortable illness like mesothelioma.
5) If the patient gives a complete free hand to the doctors and researchers, then they may not have any choice in the treatment, which they will receive. This may be difficult and risky for the patient.
What is the eligibility to participate in a mesothelioma clinical trial?
Normally, there is no specific eligibility to participate in a mesothelioma clinical trial. However, sometimes there may be certain conditions that may be imposed for participating in a mesothelioma clinical trial. These are as follows:
1) Some studies may want only first-time Volunteers. Others may permit even those who have been in other studies previously.
2) Some Studies may be random, giving no choice to the patients about the type of treatment they may receive. Others may be more specific about giving a choice to the patients.
3) Sometimes, some studies may focus on only one particular type of mesothelioma. Thus, other patients suffering from other types of mesothelioma are not eligible for such studies. For instance, a person suffering from pleural mesothelioma (mesothelioma originating from the lungs) is not eligible to participate in a study involving peritoneal mesothelioma (mesothelioma originating from the abdomen).
4) Some studies may require a person in a particular stage of cancer. Thus, others become ineligible for that study For instance, a person in the second stage of cancer becomes ineligible for a study Involving persons in the fourth stage of cancer.
5) Some studies may specifically require people of a particular sex or of a particular age group.
6) Some studies may require people of a particular background. For instance, people who are smokers or people who have worked in asbestos industries or so on.
What are the types of mesothelioma clinical trials?
There are various types of mesothelioma clinical trials. Some of them are listed below:
Prevention Trials:
These trials are directed towards finding out a way to avoid the occurrence of mesothelioma. These studies use people who do not have mesothelioma or people who have had it but now the cancer is in remission. They try to find out ways to prevent recurrence.
Screening Trials:
These trials are conducted to study whether the diagnosis and discovery of cancer is effective. People who are cancer free but have factors, which predispose them to cancer, participate in this trial.
Diagnostic Trials:
These are trials, which study about the diagnostic procedures and test their effectiveness. Patients who show symptoms of mesothelioma can participate in this trial.
Treatment Trials:
This trial tests the effectiveness of new types of treatments and the various new drugs. Volunteers for this type of trial are patients with mesothelioma.Visit here http://mesotheliomatreatment-option.blogspot.com
Mar
06
Does The Clinical Research online courses is accreditable?
Posted by: | CommentsI have BSc in Pharmacy. I am interested to work in a clinical research field. I read about many online courses in this field like “Kriger’s”. It will cost around $1000, and I am not sure if it will help me find a good job in research field in international pharmaceutical companies like Pfizer or Abbott. So if anyone of u has an idea , plz I need ur advice. Thank u in advance:)
Feb
10
Is the search for the cure for cancer more profitable than finding the cure?
Posted by: | CommentsIf you consider all the fund-raising and research development in search of cures, as well as the profits from current treatment regimes condoned by the FDA and cancer-experts, is it in the medical industry’s best interests to keep searching for the cure rather than actually find a cure for cancer?
And do you personally trust the pharmaceutical companies to provide the most effective form of treatment? Couldn’t they obtain more profits by marketing two less-effective treatments than one effective treatment?
Feb
01
This is what they don’t want the American people to know….
THE BAYH DOYLE ACT THE FIRST STEP TOWARDS COMMERCIALIZATION
This Act that Reagan introduced was intended to encourage the spreading of pharmaceutical education so that universities and the odd small business could patent the scientific discoveries from pharmaceutical research.
So, the public would pay for research that would ultimately serve the public’s health interest, in an industry that instantly became private. Our money then would now go to these big pharmaceutical companies instead of to improving the health of the American people.
The Bayh Doyle Act then has resulted in making the pharmaceuticals industry a $200 billion dollar industry every year. These are now the richest companies in the world.
And this has effectively changed the manner in which pharmaceutical education is disseminated. Now clinical trials are more biased than ever before, non-reporting of actual results is not happening, and the education behind real time data is being obscured and muddied. This is really happening people!
WHERE ARE YOUR DRUG DOLLARS GOING?
But wait, there is more. The government is behind all of it. In fact, the pharmaceutical industry is the largest lobbying body in Washington as we speak.
In 2002, the pharmaceutical industry employed almost 700 lobbyists, 26 of whom were former Congressmen, to lobby the government for higher costs in Medicare and more profits for the pharmaceutical industry.
That effort alone cost the taxpayers $91 million dollars alone, not to mention the challenges that the increased costs of Medicare incurred on the average American.
The corruption and scandal that lies behind the doors of the pharmaceutical industry is the education this country really needs, not the propaganda that we are paying for them to spit out.
I like to keep people informed of things like this, because the naysayers in this section work for and are paid by these same companies that try to keep us stupid. Their big money profits depend on keeping you and I in the dark.
We are taking back AMERICA! and not gonna take it anymore! You can believe that!
Hey Round 2, Little do you know that the pharmaceutical companies big money also finds it’s place in the lawyers pockets also. People need to open their eyes because I can see by comments like this that people just don’t KNOW!
Jan
04
Garlic, Cancer and You
Posted by: | CommentsGarlic – that oh so deliciously pungent bulb from the lily family that has been around humankind since the invention of writing, has been valued for its ability to spice up a meal, whet the appetite and to help cure a host of different ailments. Now, today’s researchers are taking a second look at garlic and are finding out that it not only helps makes things taste good, it might also play a role in preventing certain types of cancer.
Garlic and cancer
A number of studies have been done focusing on garlic’s organic allyl sulfur components and their ability to effectively inhibit the cancer process. These compounds make cells more vulnerable to the stress which is created when cells divide. Since cancer cells divide more rapidly than normal cells, they are susceptible to these specific stressors. Therefore, cancer cells have a much greater potential to suffer damage from the allyl sulfur compounds that are found in garlic.
The studies on garlic have revealed that garlic’s benefits are not limited to any specific species, to any particular tissue or even to a specific type of carcinogen. However, there is a strong link between garlic and the prevention on prostate and stomach cancers. 37 different observational studies have been done on people exploring the use of garlic and cancer prevention. Of the 37, 28 of the studies have revealed that garlic does play some role in cancer prevention.
It is important to note that these studies are observational: comparing the incidence of cancer among garlic and non-garlic consuming populations. Clinical studies are still needed for further verification, but unfortunately government funding for garlic research is limited and pharmaceutical companies are reluctant to study widely available plants that might have health benefits since there is no profit in it.
A complicated chemistry
Garlic’s chemistry is extremely complicated and how garlic products are manufactured and processed greatly effects the medicinal value of its various chemical constituents. Peeling garlic and then turning into an oil or powder can actually increase the number and variety of active compounds. The peeling process releases the enzyme allinase and kick starts the process that leads to the chemical reaction that produces diallyl disulfide. Diallyl Disulfide is also formed when garlic is crushed or chopped, however if it is cooked immediately after peeling and chopping the cancer fighting benefit of this sulfide is lost. Some secientis have recommended that you let the garlic sit for 15-20 minutes after it has been peeled in order to allow the allinase reaction to occur.
Yulia Berry is an independent health researcher and author of the best selling e-books Aloe – Your Miracle Doctor and ‘Pharmacy in Vegetables’. She distributes a weekly newsletter regarding great home remedies and has written dozens of natural health articles published on hundreds of websites worldwide. Yulia Berry’s new ebook Unlocked Secrets of Curative Garlic to be released soon.
Dec
23
Will Pharmaceutical Sales Jobs be Recession Proof?
Posted by: | CommentsIf you are a resident of Planet Earth, you are well aware that we have been in a recession. Many economists say that the recession is still alive and well. Others report that they believe it is over or very nearly over. There is definately no area of life which has not been hit by financial woes. A multitude of jobs have been lost. Companies have downsized, or closed. There are types of jobs may not have been affected as strongly by the recession as others? Are there any who have remained unscathed by our world’s economic crisis?
It would seem feasible that one of the first job areas to suffer during a recession would be sales. It stands to reason that when money gets tight, people have to be more selective of the things on which they spend their money. Purchases can be divided loosely into two classifications. There are luxury items and necessities. Luxury items are usually the first to get bumped off the list of pending purchases. Certain clothing purchases, jewelry and vacations would all fall into the luxury category. Food and fuel are two basic necessities of life.
A third necessity for a large majority of humans is medication. Many people literally depend upon their daily medications to stay alive. Pharmaceutical companies comprise of a multi-billion dollar business industry. These companies are working around the clock formulating, testing, improving and producing medications. They employ thousands of people whose job it is to travel around and talk to doctors and pharmacists about new types of prescription drugs, as they become available for market.
These sales representatives are highly trained in the area of sales, but also must have a vast knowledge of the products which they are introducing to the doctors. The sales representative will typically have a few short minutes out of a busy doctor’s day in which to make an impact on him, on behalf of the drug company. They will have to convince the doctor that this is the drug that he should be prescribing for a particular ailment. Doctors will further research the drug before they actually prescribe it, but the sales representative must gain his interest in that drug initially.
I know a person who is employed as a pharmaceutical sales representative. She is able to work from her home most of the time. However, about once a month her company will fly her to one of several other countries to meet with a small group of doctors. At those meetings, it is her job to make presentations, answer any questions the doctors may have, and generally make them comfortable with their relationship with her drug company. Sometimes with potential customers, she must make them aware of all the many reasons why they should associate themselves with her company. Her level of travel accommodations suggests that there is no recession in the pharmaceutical industry.
For as long as there are humans, there will be ailments. That means that there will always be a need for medications, and the companies who produce them. Sadly enough, people will have to forefit other purchases, if necessary, in order to be able to purchase their medications at any price. Therefore, it is a given that pharmaceutical companies will survive and thrive in any economy.
Joe Blogger is a leading authority in the field of Pharmaceutical Sales Jobs and Pharmaceutical recruitment and employment matters. Joe Blogger has written numerous informative articles relating to Pharmaceutical Sales jobs.
www.zenopa.com/pharmaceutical_sales_jobs.html
Dec
21
Aarkstore announce a new report “Pharmaceutical Sales Force Effectiveness Strategies: Evaluating evolving sales models & advanced technology for a customer centric approach” through its vast collection of market research report.
The social, demographic and economic context in which the pharmaceutical industry operates is changing dramatically, with huge implications for the industry as a whole. All these challenges have major ramifications for the way in which pharmaceutical companies market and sell the medicines they develop. With these challenges comes pressure to gain efficiencies in all facets of the business, but perhaps no aspect of pharma operations is under as much scrutiny as the sales and marketing function. The discrepancy between the growth in sales force size and the decline in prescribing makes sales force effectiveness the top challenge for pharmaceutical sales managers.
The industry has traditionally relied on aggressive marketing to promote its products. One recent study (NEJM, August 2007) estimates that, between 1996 and 2005, total real spending on pharmaceutical promotions rose from $11.4bn to $29.9bn in the United States. Another study (PLoS Med, January 2008) suggests that the true figure is closer to $57.5bn in real terms. Much of this increase in spending has gone on the expansion of the sales force. For years now there has been an unshakable belief that the bigger the sales force, the greater the market share. However, many of the industry’s biggest markets are now saturated with sales representatives, and its selling techniques are becoming increasingly ineffective. The industry has begun to embrace the reality that this model no longer guarantees growth or future profitability. The opportunity lies in moving beyond sales force growth and mass promotion into a new era of sales force effectiveness.
Key features of this report
Detailed analysis of the current state of the pharmaceutical industry, including the five major trends reshaping the pharmaceutical marketplace and their impact on the sales force.
The impact that sales force size has on sales, costs and profits in both the short and the long term. Different situations for sizing a sales force such as expansion into new markets, new product launches and downsizing are illustrated. Three different methods that companies use to size their sales force are provided.
Highlights the importance of sales force recruiting and hiring process as well as the role of training in preparing the pharmaceutical sales force for success. Practical advice on how to implement incentive plans and how to set effective SFE (Sales force effectiveness) metrics.
Use this report to
Learn how the changing social, economic and demographic context has huge implications for the way in which pharmaceutical companies will market and sell the medicines they develolp in the future.
Discover why pharma industry revenue will decline for the first time in its history and what the effects on the pharmaceutical sales force organization are.
Quick and comprehensive understanding of sales force sizing, structuring and deployment and recent trends in physician targeting.
Discover
Is the pharmaceutical sales representative an endangered species?
Why should pharma companies adopt a Key Account Management approach to their customers?
What will the expected shift in marketing and sales efforts look like?
How can sales organization be sized, structured and deployed for max. effectiveness in the new healthcare environment?
For more information, please visit :
http://www.aarkstore.com/reports/Pharmaceutical-Sales-Force-Effectiveness-Strategies-Evaluating-evolving-sales-models-advanced-technology-for-a-customer-centric-approach-34843.html
Or email us at press@aarkstore.com or call +919272852585
Special offer till 31th Dec 2009
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.
Dec
19
Aarkstore announce a new report “Pharmaceutical Sales Force Effectiveness Strategies: Evaluating evolving sales models & advanced technology for a customer centric approach” through its vast collection of market research report.
The social, demographic and economic context in which the pharmaceutical industry operates is changing dramatically, with huge implications for the industry as a whole. All these challenges have major ramifications for the way in which pharmaceutical companies market and sell the medicines they develop. With these challenges comes pressure to gain efficiencies in all facets of the business, but perhaps no aspect of pharma operations is under as much scrutiny as the sales and marketing function. The discrepancy between the growth in sales force size and the decline in prescribing makes sales force effectiveness the top challenge for pharmaceutical sales managers.
The industry has traditionally relied on aggressive marketing to promote its products. One recent study (NEJM, August 2007) estimates that, between 1996 and 2005, total real spending on pharmaceutical promotions rose from $11.4bn to $29.9bn in the United States. Another study (PLoS Med, January 2008) suggests that the true figure is closer to $57.5bn in real terms. Much of this increase in spending has gone on the expansion of the sales force. For years now there has been an unshakable belief that the bigger the sales force, the greater the market share. However, many of the industry’s biggest markets are now saturated with sales representatives, and its selling techniques are becoming increasingly ineffective. The industry has begun to embrace the reality that this model no longer guarantees growth or future profitability. The opportunity lies in moving beyond sales force growth and mass promotion into a new era of sales force effectiveness.
Key features of this report
Detailed analysis of the current state of the pharmaceutical industry, including the five major trends reshaping the pharmaceutical marketplace and their impact on the sales force.
The impact that sales force size has on sales, costs and profits in both the short and the long term. Different situations for sizing a sales force such as expansion into new markets, new product launches and downsizing are illustrated. Three different methods that companies use to size their sales force are provided.
Highlights the importance of sales force recruiting and hiring process as well as the role of training in preparing the pharmaceutical sales force for success. Practical advice on how to implement incentive plans and how to set effective SFE (Sales force effectiveness) metrics.
Use this report to
Learn how the changing social, economic and demographic context has huge implications for the way in which pharmaceutical companies will market and sell the medicines they develolp in the future.
Discover why pharma industry revenue will decline for the first time in its history and what the effects on the pharmaceutical sales force organization are.
Quick and comprehensive understanding of sales force sizing, structuring and deployment and recent trends in physician targeting.
Discover
Is the pharmaceutical sales representative an endangered species?
Why should pharma companies adopt a Key Account Management approach to their customers?
What will the expected shift in marketing and sales efforts look like?
How can sales organization be sized, structured and deployed for max. effectiveness in the new healthcare environment?
For more information, please visit :
http://www.aarkstore.com/reports/Pharmaceutical-Sales-Force-Effectiveness-Strategies-Evaluating-evolving-sales-models-advanced-technology-for-a-customer-centric-approach-34843.html
Or email us at press@aarkstore.com or call +919272852585
Special offer till 31th Dec 2009
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.